Metastatic Colorectal Cancer (mCRC)

25 clinical trials · Condition

Record	Firm	Date
A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC (NCT04856787)	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	2021-06-22
Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients (NCT03829462)	Institut du Cancer de Montpellier - Val d'Aurelle	2019-03-28
A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC) (NCT05420909)	Bristol-Myers Squibb	2019-01-28
A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC (NCT03511963)	Shanghai Henlius Biotech	2018-04-09
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications (NCT02649790)	Karyopharm Therapeutics Inc	2016-01-01
Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients (NCT02069704)	mAbxience Research S.L.	2014-10-29
Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors. (NCT01705002)	Lipomedix Pharmaceuticals Inc.	2012-10-01
Phase I/II Combination With Irinotecan- Erbitux (NCT00594984)	Bristol-Myers Squibb	2008-05-01

Every clearance here is in the API, with alerts when new ones post.